GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ondine Biomedical Inc (LSE:OBI) » Definitions » EPS (Diluted)

Ondine Biomedical (LSE:OBI) EPS (Diluted) : £-0.06 (TTM As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Ondine Biomedical EPS (Diluted)?

Ondine Biomedical's Earnings per Share (Diluted) for the six months ended in Jun. 2023 was £-0.02. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.06.

Ondine Biomedical's EPS (Basic) for the six months ended in Jun. 2023 was £-0.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.06.

Ondine Biomedical's EPS without NRI for the six months ended in Jun. 2023 was £-0.02. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.06.

During the past 3 years, the average EPS without NRIGrowth Rate was -10.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was -27.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 9.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Ondine Biomedical's highest 3-Year average EPS without NRI Growth Rate was 53.20% per year. The lowest was -157.10% per year. And the median was -10.10% per year.


Ondine Biomedical EPS (Diluted) Historical Data

The historical data trend for Ondine Biomedical's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ondine Biomedical EPS (Diluted) Chart

Ondine Biomedical Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.04 -0.05 -0.37 -0.06

Ondine Biomedical Semi-Annual Data
Dec06 Jun07 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.14 -0.03 -0.04 -0.02

Competitive Comparison of Ondine Biomedical's EPS (Diluted)

For the Biotechnology subindustry, Ondine Biomedical's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ondine Biomedical's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ondine Biomedical's PE Ratio distribution charts can be found below:

* The bar in red indicates where Ondine Biomedical's PE Ratio falls into.



Ondine Biomedical EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Ondine Biomedical's Diluted EPS for the fiscal year that ended in Dec. 2022 is calculated as

Diluted EPS (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-11.707-0)/194.588
=-0.06

Ondine Biomedical's Diluted EPS for the quarter that ended in Jun. 2023 is calculated as

Diluted EPS (Q: Jun. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-4.709-0)/194.716
=-0.02

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ondine Biomedical  (LSE:OBI) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Ondine Biomedical EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Ondine Biomedical's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Ondine Biomedical (LSE:OBI) Business Description

Traded in Other Exchanges
Address
1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.

Ondine Biomedical (LSE:OBI) Headlines

No Headlines